AU2001266338A1 - Pharmaceutical compositions for angiogenic therapy - Google Patents

Pharmaceutical compositions for angiogenic therapy

Info

Publication number
AU2001266338A1
AU2001266338A1 AU2001266338A AU2001266338A AU2001266338A1 AU 2001266338 A1 AU2001266338 A1 AU 2001266338A1 AU 2001266338 A AU2001266338 A AU 2001266338A AU 2001266338 A AU2001266338 A AU 2001266338A AU 2001266338 A1 AU2001266338 A1 AU 2001266338A1
Authority
AU
Australia
Prior art keywords
pharmaceutical compositions
angiogenic therapy
angiogenic
therapy
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001266338A
Other versions
AU2001266338B2 (en
AU2001266338B8 (en
Inventor
Motokuni Aoki
Hiromi Koike
Ryuichi Morishita
Tadashi Tanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anges Inc
Original Assignee
Anges MG Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges MG Inc filed Critical Anges MG Inc
Priority claimed from PCT/JP2001/005514 external-priority patent/WO2002000258A1/en
Publication of AU2001266338A1 publication Critical patent/AU2001266338A1/en
Publication of AU2001266338B2 publication Critical patent/AU2001266338B2/en
Application granted granted Critical
Publication of AU2001266338B8 publication Critical patent/AU2001266338B8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2001266338A 2000-06-27 2001-06-27 Pharmaceutical compositions for angiogenic therapy Ceased AU2001266338B8 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000192480 2000-06-27
JP2000-192480 2000-06-27
JP2000-388624 2000-12-21
JP2000388624 2000-12-21
PCT/JP2001/005514 WO2002000258A1 (en) 2000-06-27 2001-06-27 Medicinal compositions for angiogenic therapy

Publications (3)

Publication Number Publication Date
AU2001266338A1 true AU2001266338A1 (en) 2002-03-28
AU2001266338B2 AU2001266338B2 (en) 2006-11-09
AU2001266338B8 AU2001266338B8 (en) 2006-12-14

Family

ID=26594742

Family Applications (2)

Application Number Title Priority Date Filing Date
AU6633801A Pending AU6633801A (en) 2000-06-27 2001-06-27 Medicinal compositions for angiogenic therapy
AU2001266338A Ceased AU2001266338B8 (en) 2000-06-27 2001-06-27 Pharmaceutical compositions for angiogenic therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU6633801A Pending AU6633801A (en) 2000-06-27 2001-06-27 Medicinal compositions for angiogenic therapy

Country Status (10)

Country Link
US (2) US20030171287A1 (en)
EP (2) EP1300158B9 (en)
KR (1) KR100798566B1 (en)
CN (1) CN1274365C (en)
AT (2) ATE530197T1 (en)
AU (2) AU6633801A (en)
CA (1) CA2413768A1 (en)
DE (1) DE60134021D1 (en)
NZ (1) NZ523613A (en)
WO (1) WO2002000258A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1182874C (en) * 1999-10-29 2005-01-05 安增子摩祺株式会社 Gene therapy for diabetic ischemic disease
JPWO2002064165A1 (en) * 2001-02-13 2004-06-10 久光製薬株式会社 Cell growth inhibitor comprising ETS transcription factor or gene encoding the same
KR100562824B1 (en) * 2002-03-20 2006-03-23 주식회사 바이로메드 Hybrid hepatocyte growth factor gene which has a high expression efficiency and expresses two heterotypes of hepatocyte growth factor
CN1717254A (en) * 2002-12-02 2006-01-04 安增子摩祺株式会社 Methods for treating or preventing angiogenesis-dependent symptoms
JPWO2005021045A1 (en) * 2003-08-29 2006-10-26 アンジェスＭｇ株式会社 Gene therapy for skin diseases using needleless syringes
DE602005003211T2 (en) * 2004-03-09 2008-02-21 Tohoku Technoarch Co., Ltd., Sendai USE OF THE HEPATOCYTE GROWTH FACTOR TO PROMOTE THE INDUCTION OF VASCULAR DIFFERENTIATION
ATE493973T1 (en) 2004-06-04 2011-01-15 Teva Pharma PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN
US7608416B2 (en) * 2004-12-07 2009-10-27 The Trustees Of The University Of Pennsylvania Targeting mPGES-1 as a treatment for inflammation which avoids cardiovascular risk
US7252834B2 (en) 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
US20090214654A1 (en) * 2008-02-21 2009-08-27 Isenburg Jason C Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle
CA2720611C (en) * 2008-04-09 2016-07-12 Viromed Co., Ltd. Lyophilized dna formulations for enhanced expression of plasmid dna
JP5725489B2 (en) 2008-06-27 2015-05-27 公立大学法人大阪市立大学 Medical composition and medical kit
US20100016833A1 (en) * 2008-07-15 2010-01-21 Ogle Matthew F Devices for the Treatment of Vascular Aneurysm
US20100119605A1 (en) * 2008-11-12 2010-05-13 Isenburg Jason C Compositions for tissue stabilization
US8496911B2 (en) * 2009-07-29 2013-07-30 Vatrix CHF, Inc. Tissue stabilization for heart failure
EP2474325B1 (en) * 2009-08-31 2017-06-21 Keiichi Hukuda Drug composition for angiogenesis therapy of limb ischemia
WO2011044455A1 (en) * 2009-10-09 2011-04-14 Vatrix Medical, Inc. In vivo chemical stabilization of vulnerable plaque
US8444624B2 (en) * 2009-10-19 2013-05-21 Vatrix Medical, Inc. Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
WO2012158944A1 (en) 2011-05-18 2012-11-22 Vatrix Medical, Inc. Coated balloons for blood vessel stabilization
US9283241B2 (en) 2012-07-10 2016-03-15 Clemson University Treatment to render implants resistant to diabetes
US10639351B2 (en) 2013-10-22 2020-05-05 Helixmith Co., Ltd. Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
MX363122B (en) 2014-06-12 2019-03-11 Tx Medic Ab The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject.
US11554179B2 (en) 2018-07-19 2023-01-17 Helixmith Co., Ltd Lyophilized pharmaceutical compositions for naked DNA gene therapy
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814509A (en) * 1994-04-28 1998-09-29 Tanabe; Tadashi Prostacyclin synthase derived from human
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
JP3058828B2 (en) * 1996-03-15 2000-07-04 株式会社巴川製紙所 Polyester resin for electrophotographic toner, method for producing the resin, and toner for electrophotography using the resin
US5785965A (en) * 1996-05-15 1998-07-28 The Board Of Trustees Of The Leland Stanford Junior Univ. VEGF gene transfer into endothelial cells for vascular prosthesis
US20030219380A1 (en) * 1997-11-07 2003-11-27 Annie Fong Method of determining an efficacious dose of a drug
AUPP459998A0 (en) * 1998-07-09 1998-07-30 Monash University Modulation of haemopoietic cell activity and inflammation via the ets-1 gene and agents useful for same
DE19940012A1 (en) 1999-08-24 2001-03-08 Karin Faerber Eukaryotic expression plasmid useful for treating peripheral arterial occlusive disease, comprises two expression cassettes, one containing the gene for human vascular endothelial growth factor VEGF165
JP2001199903A (en) * 1999-11-09 2001-07-24 Eizo Mori Nucleic acid-containing complex
DE60128540T2 (en) * 2000-02-09 2008-01-31 Bas Medical, Inc., San Mateo USE OF RELAXIN FOR TREATMENT OF VASCULAR DISORDERS
US6533541B1 (en) * 2001-12-04 2003-03-18 Honeywell International, Inc. High energy particle arrestor for air turbine starters

Similar Documents

Publication Publication Date Title
AU2001266338A1 (en) Pharmaceutical compositions for angiogenic therapy
AU781269C (en) Pharmaceutical compositions
AU2002222118A1 (en) Pharmaceutical compositions for inhalation
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
AU2002218250A1 (en) Medicament dispenser
AU3192700A (en) Medicinal compositions
AU2002223562A1 (en) Medicament dispenser
AU3556400A (en) Pharmaceutical compositions
AU2005300A (en) Medicinal compositions
AU1887401A (en) Medicinal composition
AU2002214324A1 (en) Medicinal compositions
AU2001284444A1 (en) Preparations for oral administration
AU2001290239A1 (en) Medicinal composition
AU2001256201A1 (en) Device for administering implants
AU2002221115A1 (en) Medicinal compositions having improved absorbability
AU6715600A (en) Pharmaceutical formulations
AU2001273919A1 (en) Pharmaceutical compositions
AU6460400A (en) Pharmaceutical compositions
AU2002215114A1 (en) Pharmaceutical compositions for inhalation
AU4977300A (en) Pharmaceutical formulations
AU1385801A (en) Pharmaceutical formulations
AU6460200A (en) Pharmaceutical compositions
AU4085201A (en) Pharmaceutical composition
AU6460300A (en) Pharmaceutical compositions